Also didn't include anything about the ~200,000 ARDS cases in the US for which there is no current treatment.
I think BP's expectations for Covid related ARDS are very conservative ( as they note)
0.5% ongoing incidence rate with a 10% market share. If they expect Covid to remain in the population like influenza then a higher rate of incidence can be expected - I think the flu is >5%
With some minor changes in assumptions a significantly higher valuation impact for Covid 19 ARDS can reasonably be achieved.
I understand BPs need to be conservative at this early stage
Bell Potter Daily Pack 16 April 2020, page-15
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.070(4.78%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.46 | $1.37 | $6.047M | 4.308M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 220242 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 2520 | 3 |
View Market Depth
| Last trade - 13.37pm 09/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |